Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Firms / L•••• G••••• M••••••••• L•••

L•••• G••••• M••••••••• L•••

Institutional venture firm · probableSan Francisco, CAl•••••••••.comSEC registered investment adviser

L•••• Capital is dedicated to advancing healthcare through disciplined, data-driven investment in biotechnology. Our mission is to identify and fund life-changing therapeutics that will generate superior long-term returns for investors. Our approach involves thorough event tracking, clinical trial underwriting, and proactive risk management to understand the intrinsic value of each opportunity.

venture manager, reported GAV $548M across 5 vehicles

Importance
30
moderate
Active deployment
25
moderate
Emerging
0
low
Completeness
69
high
Freshness
98
high
Research priority
11
low
Identity and regulatory footprint
Headquarters
San Francisco, CAadviserinfo.sec.gov
Office address
1 LETTERMAN DRIVE, BLDG C, STE C3-350, San Francisco, CA, 94129adviserinfo.sec.gov
Business phone
415-801-4660adviserinfo.sec.gov
SEC adviser type
registered investment adviseradviserinfo.sec.gov
SEC exemption claimed
unknown
Latest Form ADV
Apr 22, 2026
Private funds reported
5 (4 venture capital funds)adviserinfo.sec.gov
Private fund gross assets
$2.3Badviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
Regulatory AUM
$2.3Bthe adviser's RAUM, a regulatory measure, never a fund size
Employees
9
Owners on Schedule A
L•••• G••••• M••••••••• G• L•• (General Partner), NA
business email
ir@logoscapital.comlogoscapital.compublished by the subject
business phone
415-801-4660adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
1 observed deals
Stated (the firm’s website)
Sectors
healthcare, biotech
Stages
not stated or not yet read
Geography
global
Check size
not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation
series b 100%
Stage at first entry
series b 100%
Sectors
unknown 100%
lead rate 0%follow-on rate 0%new logos, 12 months 0
Funds and vehicles
5 reported
VehicleTypeVintageLifecycleReported GAVOwnersForm D soldLatest Form D
L•••• O••••••••• F••• I• L•Opportunity fund2023 form d first saleActive deployment$183M
Apr 26, 2024
106$284MJul 19, 2024
L•••• S•• I• L•SPV or co-invest vehicle2022 adv first reportedActive deployment$7.1M
Apr 26, 2024
21unknownunknown
L•••• O••••••••• F••• I•• L•Opportunity fund2021 form d first saleMature$224M
Apr 26, 2024
96$208MMay 10, 2021
L•••• O••••••••• F••• I• L•Opportunity fund2021 adv first reportedMature$114M
Apr 26, 2024
91$0Apr 8, 2020
L•••• O••••••••• F••• I• L•Opportunity fund2019 form d first saleMature$20.1M
Apr 26, 2024
27$44.0MFeb 26, 2020
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
15 current, 4 departed
Platform and operations
IR@logoscapital.com (published by the subject)FactVenture organization websites (about, team, portfolio, thesis, news pages)
D•••• G••••
General Counsel / Chief Compliance Officer
Platform and operations
4 departed (kept with end dates)
Investments on record
0 edges, 0 companies, 0 partner-attributed
No investment on record yet. Edges arrive from the firm’s portfolio page, financing announcements, and Form D board seats.
Co-investors
0 relationships from shared deals, counted for the whole firm
No co-investor relationship yet: these are derived only from rounds and portfolio listings the graph has seen both investors on.
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
12 dated events
  1. Sep 16, 2026
    D•••• G•••• (General Counsel / Chief Compliance Officer) no longer on the team page of L•••• G••••• M••••••••• L•••
  2. Mar 29, 2024
    L•••• O••••••••• F••• I• L• first reported on Form ADV by L•••• G••••• M••••••••• L••• (Venture Capital Fund), GAV $182,891,684
  3. Mar 29, 2024
    V••••••• •••• Y•• (Chief Financial Officer) no longer on Schedule A of L•••• G••••• M••••••••• L•••
  4. May 1, 2023
    D•••• A••• G•••• joined Schedule A of L•••• G••••• M••••••••• L••• as Chief Compliance Officer & General Counsel
  5. May 1, 2023
    C•••••• L••••• G•••••••• joined Schedule A of L•••• G••••• M••••••••• L••• as Chief Financial Officer
  6. Mar 31, 2023
    E••••• C•••• C••••••• (Chief Operations Officer / Limited Partner) no longer on Schedule A of L•••• G••••• M••••••••• L•••
  7. Mar 31, 2023
    I•••••• L••• S••••••••• (Managing Member / Limited Partner) no longer on Schedule A of L•••• G••••• M••••••••• L•••
  8. Mar 31, 2022
    L•••• S•• I• L• first reported on Form ADV by L•••• G••••• M••••••••• L••• (Venture Capital Fund), GAV $18,178,921
  9. Mar 31, 2022
    L•••• O••••••••• F••• I•• L• first reported on Form ADV by L•••• G••••• M••••••••• L••• (Venture Capital Fund), GAV $95,856,484
  10. Mar 31, 2021
    L•••• O••••••••• F••• I• L• first reported on Form ADV by L•••• G••••• M••••••••• L••• (Venture Capital Fund), GAV $212,345,618
  11. Dec 23, 2019
    L•••• O••••••••• F••• I• L• first reported on Form ADV by L•••• G••••• M••••••••• L••• (Hedge Fund), GAV $25,300,000
  12. Jul 26, 2019
    L•••• G••••• M••••••••• L••• first filed Form ADV (IA)
Classification history
  1. Sep 15, 2026
    Institutional venture firm (probable, 80%, cls-1)
    venture manager, reported GAV $548M across 5 vehicles
  2. Sep 12, 2026
    Institutional venture firm (probable, 80%, cls-1)
    venture manager, reported GAV $528M across 4 vehicles
Evidence
50 observations from 3 sources
Every observation behind this profile, with its source, date and class
FactValueEffectiveClassSource
Why admittedvc_funds_reportedApr 22, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
SEC adviser typeregistered_investment_adviserApr 22, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
SEC adviser typeregistered_investment_adviserApr 26, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
First Form ADV filing2019-07-26Apr 26, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Adv history loadedadv-hist-1Sep 12, 2026FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Latest Form ADV filing2026-04-22Apr 22, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Latest Form ADV filing2024-04-26Apr 26, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
SEC statusApprovedApr 22, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
SEC status effective2019-08-26Apr 22, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Venture share of reported funds1Apr 26, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Business phone415-801-4660Apr 22, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Business phone415-801-4660Apr 26, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
DescriptionL•••• Capital is dedicated to advancing healthcare through disciplined, data-driven investment in biotechnology. Our mission is to identify and fund life-changing therapeutics that will generate superior long-term returns for investors. Our approach involves thorough event tracking, clinical trial underwriting, and proactive risk management to understand the intrinsic value of each opportunity.
meta description
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
DescriptionL•••• Capital is dedicated to advancing healthcare through disciplined, data-driven investment in biotechnology. Our mission is to identify and fund life-changing therapeutics that will generate superior long-term returns for investors. Our approach involves thorough event tracking, clinical trial underwriting, and proactive risk management to understand the intrinsic value of each opportunity.
meta description
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Employees9Apr 22, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Employees9Apr 26, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
HeadquartersSan Francisco, CAApr 22, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
HeadquartersSan Francisco, CAApr 26, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Office address1 LETTERMAN DRIVE, BLDG C, STE C3-350, San Francisco, CA, 94129Apr 22, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Office address1 LETTERMAN DRIVE, BLDG C, STE C3-350, San Francisco, CA, 94129Apr 26, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Legal formLimited PartnershipApr 22, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Portfolio pagehttps://l•••••••••.com/
0 entries read
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Portfolio pagehttps://l•••••••••.com/
0 entries read
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Private funds reported5Apr 22, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Private funds reported6Apr 26, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Private fund gross assets (reported)$2.3BApr 22, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Private fund gross assets (reported)$1.5BApr 26, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Regulatory AUM (adviser, not fund size)$2.3BApr 22, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Regulatory AUM (adviser, not fund size)$1.5BApr 26, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Stated geographyglobal
geography words on the home page
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Stated geographyglobal
geography words on the home page
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Stated sectorshealthcare,biotech
sector words on the home page
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Stated sectorshealthcare,biotech
sector words on the home page
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Team pagehttps://l•••••••••.com/
10 name/title pairs read
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Team pagehttps://l•••••••••.com/
8 name/title pairs read
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Venture funds reported4Apr 22, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Venture funds reported5Apr 26, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Websitehttps://l•••••••••.com/Apr 26, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Site titleL•••• Capital | Advancing healthcare through investments in biotechnology
title tag
Sep 16, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)
Site titleL•••• Capital | Advancing healthcare through investments in biotechnology
title tag
Sep 14, 2026FactVenture organization websites (about, team, portfolio, thesis, news pages)